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Abstract
Background: Obtaining a research participant’s voluntary and informed consent is the bedrock of sound ethics
practice. Greater inclusion of children in research has led to questions about how paediatric consent operates in
practice to accord with current and emerging legal and socio-ethical issues, norms, and requirements.
Methods: Employing a qualitative thematic content analysis, we examined paediatric consent forms from major
academic centres and public organisations across Canada dated from 2008–2011, which were purposively selected
to reflect different types of research ethics boards, participants, and studies. The studies included biobanking,
longitudinal studies, and gene-environment studies. Our purpose was to explore the following six emerging issues:
(1) whether the scope of parental consent allows for a child’s assent, dissent, or future consent; (2) whether the
concepts of risk and benefit incorporate the child’s psychological and social perspective; (3) whether a child’s ability
to withdraw is respected and to what extent withdrawal is permitted; (4) whether the return of research results
includes individual results and/or incidental findings and the processes involved therein; (5) whether privacy and
confidentiality concerns adequately address the child’s perspective and whether standard data and/or sample
identifiability nomenclature is used; and (6) whether retention of and access to paediatric biological samples and
associated medical data are addressed.
Results: The review suggests gaps and variability in the consent forms with respect to addressing each of the six
issues. Many forms did not discuss the possibility of returning research results, be they individual or general/aggregate
results. Forms were also divided in terms of the scope of parental consent (specific versus broad), and none discussed a
process for resolving disputes that can arise when either the parents or the child wishes to withdraw from the study.
Conclusions: The analysis provides valuable insight and evidence into how consent forms address current ethical
issues. While we do not thoroughly explore the contexts and reasons behind consent form gaps and variability, we do
advocate and formulate the development of best practices for drafting paediatric health research consent forms. This
can greatly ameliorate current gaps and facilitate harmonised and yet contextualised approaches to paediatric health
research ethics.
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Background
Obtaining a research participant’s voluntary and informed
consent is the bedrock of sound legal and ethics practice.
From an ethical and human rights perspective, informed
consent protects the research participant from potential
harm and promotes his or her autonomy and dignity.
From a legal perspective, it can act as a waiver to the com-
mon law tort of battery or negligence in medical research.
Childrena constitute an important population sub-
group in health research, and their growing inclusion in
research has led to questions about how paediatric con-
sent operates in practice. This is partly attributable to an
expanding body of evidence that indicates tremendous
gaps, variability, and apparent inconsistency in the content
of consent forms for health research, even for similar stud-
ies or at different sites within the same study [1-8]. This
may be due to, in part, new challenges raised by health re-
search that are not addressed or settled in current guide-
lines. Another reason, often stated by research ethics
boards (REBs) themselves, may be sensitivity to local con-
cerns of participant communities, administrations, and
cultures [9]. While some flexibility and diversity is war-
ranted, consent form variability and inconsistency should
be scrutinised for several reasons. First, large-scale study
forms that do not consider the growing importance that
many significant research funders place on broad data
sharing may impede data flow through varying modalities
of consent, data or sample coding, and data or sample
transfer policies [10]. Second, from an ethical viewpoint,
inconsistency and a lack of harmonisation may unevenly
protect research participants [11]. Third and most cru-
cially, it can undermine the trust that parents b, children,
researchers and society place in research enterprises, and
ultimately cause harm to children’s rights [12,13].
Considering the rapid research developments in areas
such as biobanking, longitudinal studies, gene-gene or
gene-environment studies, and exome- or genome-wide
association studies, it is important to examine the
approaches in consent forms that address several key
issues in paediatric research that the literature identifies as
emerging [14-24], namely those arising under the domain
of: (1) the scope of consent of the parent and/or child; (2)
risks and benefits; (3) the right of withdrawal; (4) return of
research results and incidental findings; (5) privacy and
confidentiality; and (6) retention of and access to the
child’s data and/or samples.
These issues have significant impact on the content of
the informed consent forms and its process. In response
to the growing research in the field of paediatrics, we hope
to draw attention to emerging ethical issues in paediatric
research where further harmonisation could surface. Our
objective in the first part of the analysis is a) to find out
how much information refers to these emerging issues,
and b) to evaluate the quality using a structured checklist
based on the best practices. Since we noted a lack of
consistency, in the second part, we propose some best
practices for the development of the consent forms. This,
we contend, is a pressing need because children are vul-
nerable and require protection [25], and because their spe-
cific health interests via research require promotion.
Addressing the emerging issues in paediatric research con-
sent forms will facilitate harmonised and yet contextua-
lised approaches, hopefully promoting a safer and
healthier world for children.
Methods
Sample identification
REB-approved assent and consent forms dated 2008–2011
for paediatric research from across Canada were collected.
Members of Canada’s Maternal Infant Child and Youth
Research Network (MICYRN), which consists of 17 child
health research organisations at academic health centres
affiliated with universities or medical schools in Canada,
were contacted and asked to provide copies of their REB-
approved informed consent forms. In addition, we
searched websites of large organisations engaged in
paediatric research across Canada using our personal
knowledge of ongoing research projects at leading hospi-
tals and research institutes. By way of purposive sam-
pling, we deliberately collected consent forms arising
from observational, genetic, longitudinal, and clinical
trial studies. Through the end of 2011, we collected and
reviewed 65 forms.
Figure 1 depicts the inclusion and exclusion criteria. We
excluded assent forms (n = 12) since they are addressed
only to children, are somewhat distinct from consent
forms, and will be the subject of a separate paper. We also
excluded non-Canadian forms (n = 6) and forms (n = 4)
that consisted only of research conducted with pregnant
women and/or parents and not with neonates or children.
The resulting data set consisted of 43 documents that met
our inclusion criteria and addressed at least one of our
emerging issues. They were selected from major academic
research centres or public health organisations that
included forms (with some overlap) for studies that
included biobanks, clinical trials, longitudinal studies, ob-
servational studies, as well as paediatric research consent
form templates (n = 16) drafted by research institutions,
hospitals, or government agencies.
Data abstraction
Following a modified qualitative thematic content analysis
[26], the content of the consent forms was coded using an
‘a priori’ coding approach based on emerging issues falling
under six domains (Figure 2). These domains were framed
as determining whether: (1) the scope of parental consent
allows for a child’s assent, dissent, or future consent; (2)
the concepts of risk and benefit incorporate the child’s
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Figure 2 Summary of emerging issues in six domains.
Figure 1 Flow chart with the results of the search strategy.
Dove et al. BMC Medical Ethics 2013, 14:5 Page 3 of 10
http://www.biomedcentral.com/1472-6939/14/5
psychological and social perspective; (3) a child’s ability to
withdraw is respected and to what extent withdrawal is
permitted; (4) the return of research results includes indi-
vidual results and/or incidental findings and the processes
involved therein; (5) privacy and confidentiality concerns
adequately address the child’s perspective and whether
standard data and/or sample identifiability nomenclature
is used; and (6) retention of and access to paediatric bio-
logical samples and associated medical data are addressed.
These domains (and the sub-issues within each) were
chosen to provide a benchmark by which to judge how
the issues were addressed in the consent forms and be-
cause they represent, in our opinion and experience as
paediatric health ethics researchers, the most debated and
unresolved in the field. Two reviewers independently
screened the consent forms (ESD and ML). Any discrep-
ancies were reconciled and checked by another evaluator
(DA). The analysis consisted of a review of the written in-
formation in the forms, which was extracted and pre-
sented in tables.
Results
The results of our research are summarised in Table 1
(see also Additional file 1).
Consent
Thirty percent of the forms used specific consent (i.e.
the participant is informed in a detailed fashion of the
research objectives, procedures, risks, benefits, and fu-
ture uses of data and samples collected), while 42% used
broad consent (i.e. the participant is informed that data
and samples may be used in future, unspecified studies).
The remainder either did not specify the scope, as they
were template forms, or presented an option for specific
or broad consent. Fifty-six percent of the forms did not
address a child’s ability to dissent; 49% of the forms
addressed neither assent nor the potential for future re-
consent at the legal age of majority, while 30% addressed
assent with qualifications such as a specific age.
Risks and benefits
Only a quarter of the forms (25.6%) addressed financial,
social, or psychological issues in the context of potential
risks. One form – a template – addressed all three issues.
Three forms explicitly considered cumulative harms for
the child participant. To classify ‘benefit’, we distinguished
a direct benefit (i.e. a tangible positive outcome whereby
there is an intervention intended to prevent, diagnose, or
treat illness or injury) and indirect benefit (i.e. benefits to
other children of the same age or with the same condition,
or benefits that are not related to the research objectives
as such that could include gifts or payments). Sixty-seven
percent of the forms expressed indirect benefits to re-
search participants, often in the form of altruistic notions
of helping society benefit from greater knowledge of a par-
ticular disease or childhood development. One form
related to a clinical genetic study indicated a direct benefit
to the child. Two forms (in the context of clinical trials)
indicated both a potential direct benefit to the child as
well as indirect benefits to society or other paediatric
patients in the future.
Withdrawal
Sixty-five percent of the forms addressed a child’s pos-
sible ability to withdraw, none of which imposed qualifi-
cations such as demonstrable competence and maturity
in making such a decision. Other forms, however,
addressed the right to withdraw only to the parents and
not to the child. For example, one consent form for a
study to evaluate the safety and immunogenicity of a
vaccine in children aged 6 months to 18 years stated
that: ‘Taking part in this study is entirely your choice.
You may decide not to enrol your child and you may
withdraw your child from the study at any time.’ Indeed,
no mention was made of the right of the child, even in
adolescence or teenage years, to independently with-
draw, and there was no assent form associated with this
consent form in which such information could have
been included. Regarding the extent of withdrawal, only
16% stated that all unused samples and/or data would be
destroyed upon a request to withdraw; two forms stated
that there would be no further use of the data and/or
samples, and one stated that data collected up until the
declaration of withdrawal would not be removed. None
of the forms disclosed a process for handling ‘informa-
tional entanglement’, i.e. parental disagreement on with-
drawal between themselves or with the mature minor.
Return of research results and incidental findings
Sixty percent of the consent forms addressed the possible
return of research results. However, there was no consen-
sus, with approximately 15% of the total number of forms
each indicating: no return, return of general/aggregate
results, or, of individual research results (including inci-
dental findings), or, the return of both general/aggregate
and individual research results. There were also various
processes involved for the return, with some studies opt-
ing for a liaison with an independent laboratory to confirm
an incidental finding, as well as providing the option of
genetic counsellors to explain the implications of the find-
ing. All of the forms addressing return of research results
(other than a no return policy) revealed that the research-
ers would return the results, though one clinical trial form
stated that the patient’s doctor would possibly return indi-
vidual results and incidental findings. Most of the genetic
study or biobank consent forms that mentioned incidental
findings stated that in addition to disclosure of research
results by the researchers, participants had the option for
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an independent genetic clinic to confirm test results and
for genetic counsellors to discuss such findings or genetic
test results.
Privacy and confidentiality
None of the forms disclosed any information about a par-
ent’s qualified or unqualified right to access information
concerning their child, though indirectly related, one form
discussed the situation of a child’s pregnancy while en-
rolled. One-third of the forms did not specify a particular
manner of protecting data and sample identifiability, other
than a general statement of a commitment to keep all in-
formation confidential and protected, but 58% used the
word ‘coded’ for data and/or samples. Only 9% stated that
data and/or samples would be anonymised.
Retention of and access to child’s data and/or samples
Forty-two percent of the forms disclosed that data/sam-
ples would be retained and disclosed the period of time
(including if it was an indefinite period), or in the case
of template forms, stated that researchers should specify
the retention period(s). Twenty-eight percent stated that
data/samples would be retained, but did not specify a
period, while 9% disclosed that samples would be held
for a period of time (in these cases, indefinitely), but did
not specify a period for data retention. Lastly, 47% did
not discuss whether data/samples would be transferred
to another location (e.g. province, country) during or
after the study. Forty percent disclosed that data/samples
Table 1 Emerging issues in paediatric research consent
forms
Emerging issues in paediatric research discussed
in consent forms
N total (43) %
1. Consent
Scope of parental consent
Specific 13 30
Broad 18 42
Broad or Specific (option) 2 5
Not addressed 10 23
Child’s ability to dissent
Addressed 19 44
Not addressed 24 56
Possibility for child’s assent and/or future consent
Assent or future consent addressed 22 51
Neither addressed 21 49
2. Risks and benefits
Financial, social or psychological issues as potential
risks
11 26




Direct or combination of direct/indirect 3 7
3. Extent of withdrawal
Ability for child to withdraw
Addressed 28 65
Not addressed 15 35
Extent of withdrawal
All data/samples destroyed 7 16
No further use of data/samples 1 2
Retention of data/samples collected to date 3 7
Not addressed or unspecified 32 74
Process for handling parental-child disagreement on
withdrawal
0 0
4. Return of research results and incidental
findings
Not addressed 17 40
Addressed 26 60
No return 6 14
General/aggregate results return 7 16
Individual results return 7 16
General/aggregate and individual results return 6 14
Any return of results that include incidental findings
(with or without option)
8 19
Table 1 Emerging issues in paediatric research consent
forms (Continued)
5. Privacy and confidentiality
Scope of parental right to access information
concerning their child
0 0




6. Transfer and data sharing
Retention period(s) of data/samples
Indefinite 12 28
Specified time periods 18 42
Combination of indefinite and specified time periods,
depending on whether material is data or samples
4 9
Not addressed 9 21
Access to data/samples
No transfer 2 5
Disclosure that data/samples may be transferred to
another location
17 40
Disclosure and discussion of procedure for external
data/sample transfer
4 9
Not addressed 20 47
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could be transferred to another location, and 9% went
beyond simple disclosure and also stated the transfer
process of the data/samples. Two forms explicitly stated
that there would be no transfer of data/samples outside
of the study site.
Discussion
The results indicate incongruent approaches to addres-
sing emerging issues, if indeed they are addressed at all.
There are several explanations for this, and each issue
may manifest different rationales for variability. With re-
spect to consent, for example, it is generally accepted
that the failure to address in some capacity a child’s
assent and then later consent as they mature (if the re-
search project continues over a prolonged period) can
undermine the integrity of the project and create
schisms in the current and future protection of a child’s
wellbeing and developing autonomy. These issues are of
particular importance in longitudinal and biobanking
studies that intend to use samples and data indefinitely.
But re-contact, perhaps in studies not specifically longitu-
dinal in nature, may be regarded as unforeseen, unfeasible,
or unrealistic. Hence, an explanation for the common im-
plementation of ‘broad consent’ in the consent forms we
reviewed may be that it is viewed as the most practical, ef-
ficient, and appropriate scope of consent, provided the
samples and data are coded rather than anonymised so
that re-contact is possible. It should be noted that broad
consent was largely seen, as expected, in the longitudinal
and biobanking research studies.
That the majority of the consent forms we analyzed
did not address cumulative or non-physical risks may
speak to the definitional ambiguity of ‘risk’ and the ten-
dency to focus on physical risks. Risk is defined in Cana-
da’s 2010 Tri-Council Policy Statement (TCPS) [27] c as
‘a function of the magnitude or seriousness of the harm,
and the probability that it will occur’ (TCPS, Ch. 2B),
but this does not address the ambit of harm. In paediat-
ric research, harm may encompass psychological, social,
financial, and community risks, particularly in genetic,
biobanking, and longitudinal research. This is more than
an ethical concern. In Canada, full disclosure of risks in
research is legally required [28,29]. Along the same lines,
given that most forms stated that indirect benefits (e.g. a
societal benefit from biomedical advancement) would be
achieved, one must conclude that the research projects
entailed no more than ‘minimal risk’ in order to receive
REB approval, as required by the TCPS (Art. 4.6). Yet, it
remains an open question whether these projects truly
pose a minimal risk if they do not disclose non-physical
risks, consider cumulative risks, or consider risks from
the perspective of the child whose perspective may differ
drastically depending on age [30].
The lack of specificity in some of the forms that the
child could withdraw rather than the parent providing the
authorisation, and the lack of a resolution procedure for
withdrawal conflicts between children and parents, may
be due to normative guidelines that generally encourage,
rather than require, researchers to respect a child’s deci-
sion to withdraw from research if the child has the cap-
acity and maturity to make an independent choice [19,31].
The consent forms that failed to clearly state to the par-
ents that withdrawal may not in fact be absolute could be
due to instances where data and samples are irretrievably
de-linked to an identifiable person (i.e. they are anon-
ymised). Yet, almost no forms indicated anonymisation
was involved, so this is only a partial explanation. This also
leaves open the question as to whether parents or children
are aware that should they later change their mind about
participating in a study that has anonymised their data or
samples, destruction of their data or samples is no longer
possible as they cannot be identified.
The return of research results has garnered significant
discussion, especially with the advent of whole genome
and exome sequencing [20,32,33]. Incidental findings,
defined as ‘unanticipated discoveries made in the course
of research but that are outside the scope of the research’
(TCPS Article 3.4), are becoming increasingly important
as data-intensive science expands and next generation se-
quencing technologies are employed [34,35]. Currently,
there is neither national nor international consensus on
the treatment of incidental findings in paediatrics, and the
consent forms we reviewed reflect this variability and con-
tinuing lack of consensus, with respect to both return of
research results and incidental findings. In cases where
results reveal a clinically significant condition for which
there is current treatment or prevention, the parents can-
not refuse to know and the child’s right to medical care
prevails [14,21,36]. In other situations, researchers – and
parents – may opt to wait until the child is mature enough
or reaches majority before disclosing research results if the
results are not materially relevant until the child reaches
adulthood. Either way, the potential for these situations,
especially if their possibility is known at the time of con-
sent, should be explained in the consent form and further
elaborated upon by the individual obtaining consent. Simi-
larly, consent forms should be clear if the child’s consent
or assent to receiving the information would be sought so
as to not compromise the child’s ‘right to an open future’
[37], and if the ‘right not to know’ necessarily includes the
right not to have information included in the medical rec-
ord if it entails an actionable result.
It is a positive sign that most of the forms we analysed
provided standardised nomenclature for sample or data
identifiability (e.g. ‘coded’), since terminological confu-
sion has long been an issue [38]. However, standardised
nomenclature may be seen as only the first step to
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addressing privacy and confidentiality concerns. Challenges
to privacy and confidentiality are amplified by genomics
and other biomedical research projects [39], which are
often internationally collaborative and engage in perpetual
data linkage across jurisdictions. Biobanking or genetic re-
search consent forms may need to declare that neither
anonymised nor coded data and samples can guarantee
privacy, as knowledge of even a small number of genetic
variants can lead to matching of samples to individuals
with a high level of confidence (we did not observe consent
forms that disclosed this potential privacy risk).
All of the consent forms assumed parents could access
research-related information about their child. And yet,
multiple tensions can arise between the child’s privacy
interests and the parents’ general legal right to their child’s
health information [40-42]. For example, a child may not
want her parents to know about a pregnancy test result or
habitual drug use, but this desire could conflict with legal
duties of parental access to health information that com-
pel a researcher to disclose such information. At a mini-
mum, consent forms should disclose the kind or extent of
information communicated to the parent and information
which shall require the child’s consent.
Lastly, while ethical norms generally support transfer of
data and samples with certain safeguards, there is continu-
ing debate about the parameters of that transfer and the
various organisational safeguards, technological measures,
and physical measures that should be adopted and
updated – and disclosed – in the consent form. Research
participants remain woefully uninformed of the transfer of
their samples and data, particularly when it may carry a
commercial use [43]. Devising and disclosing a method for
listing all approved projects that are accessing the data
and/or samples could alleviate this. While it may be the
case that all of the consent forms we analysed that did not
address transfer of data and samples simply did not envi-
sion transfer, in the absence of explicit disclosure that ‘no
transfer will occur’, uncertainty remains and creates the
risk of future ethical concerns with maturing children.
Study limitations
Our study had some limitations. It relied on our purpos-
ive sampling derived from Canada, which may not be
generalisable to other countries. Our data focuses on
emerging ethical issues rather than on the context of the
consent process or on the quality of consent form infor-
mation and its actual comprehension by participants.
These are two critically important topics discussed else-
where in the literature [44-46]. Similarly, the amount
and quality of information extracted from the consent
forms regarding these six issues cannot provide an esti-
mated average that is generalisable to all consent forms,
though the range of issues in our purposive sampling
reveals important gaps. Some types of consent forms
may have been underrepresented, such as qualitative re-
search or community setting research. There are other
emerging issues impacting the consent process that were
not considered in this study due to resource constraints,
but are worthy of future reviews, such as the issue of
incentives for participating in research. This is an area
that is rapidly becoming a point of controversy; offering
monetary payments, gift certificates, or toys to parents or
children who participate in research touch on ethical
issues of undue influence and voluntariness [47-50]. Des-
pite these limitations, this research addresses important
gaps in the literature by incorporating evidence regarding
emerging ethical issues that will in turn improve the use-
fulness of paediatric consent forms.
Towards best practices
As our Discussion section notes, divergence in these six
distinct domains in paediatric research reflects various
factors. The rapidly evolving nature of science and tech-
nology can hamper the ability of researchers and REBs
to keep abreast of socio-ethical discourse surrounding
the inclusion of various types of emerging issue informa-
tion. But, it is insufficient to only identify problem areas
and explanations in the current environment. Remedies
should be offered as well. Therefore, we suggest some
best practices that can improve consent forms and facili-
tate harmonised and yet contextualised approaches to
ethical norms in paediatric research.
We opt for best practices deliberately. In the modern,
diverse research environment, where there is a plethora
of possibilities (sometimes overlapping), not all paediat-
ric research is alike. Designing a standard template for
consent forms other than for the most basic provisions
would restrict the flexibility needed to accommodate sci-
entific developments and local contexts [39]. Best prac-
tices, however, can serve as useful general guidance to
researchers when they design their paediatric research
projects and draft consent forms. They can also help
make REBs more aware of key issues and better scrutin-
ise consent forms for ethical compliance, and can help
ensure REBs maintain a flexible and innovative approach
to template consent forms. A set of best practices can
encourage dialogue between REBs and researchers to en-
sure that each informs the other of emerging issues and
to not rigidly adhere to document templates for wording
and formatting. Finally, best practices can help catalyse
the growing importance of paediatric research and serve
as a blueprint for further development of standards and
guidance, such as online educational and practical tools
to enhance understanding of the emerging issues.
Building on the Best Practices for Health Research
Involving Children and Adolescents [14], we propose a
non-exhaustive list of what we consider to be best
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Table 2 Best practices for drafting paediatric research consent forms in Canada
Emerging issue Best practices
Scope of parental consent
Broad consent • The possibility of future, unspecified research uses should be mentioned prior to obtaining
consent and the consent form should be worded accordingly.
Ability to assent/provide future consent • When the child is considered to be legally able to provide consent, consent should be
renewed, if feasible.
• Where feasible, data and/or samples should be coded (not anonymised) in order to allow
researchers to maintain contact with the child.
Ability to dissent • The possibility of a child’s right to dissent, provided there is an ability to understand the
significance of research or his/her role in it, should be disclosed.
Risks and benefits
Financial, social, and psychological issues • Consideration of potential harms must include physical as well as psychological, social or
financial harms.
Cumulative harms considered in assessing
individual harms
• Cumulative harms should be considered.
How ‘benefit’ is characterised • Risks and benefits should be considered from the child’s perspective.
Withdrawal
Ability for withdrawal • The child’s ability to withdraw should be explicitly disclosed, as well as any circumstances that
might limit the ability (e.g. if immediate withdrawal could harm the child).
Extent of withdrawal • The extent of the ability to withdraw should be explicitly disclosed (e.g. if data and/or samples
are anonymised, the consent form should state that withdrawal is not feasible).
Informational entanglement • The potential for a child and parents to disagree about whether to withdraw, and its potential
impact on the research project, should be described.
Return of research results and incidental
findings
The potential and process for returning research
results and incidental findings
• The potential for disclosing research results and incidental findings, as well as its process
(including who discloses and the possibility for entitlement to non-disclosure), should be
described.
Returning actionable individual results and
incidental findings
• Individual research results and incidental findings that have clinical significance should be
communicated to the child and/or parents when either prevention or treatment is available
during childhood, and with adequate counselling provided. The interconnected nature of the
potential risks and benefits of such communication should be disclosed.
Duty to receive information • Parents should be made aware that they will receive clinically significant information about
conditions that are preventable or treatable during childhood.
Privacy and confidentiality
Parents’ right to access information concerning
their child
• In research projects that collect and use particularly sensitive information, such as pregnancy
status, drug use, or sexual history, consent forms should disclose what information will and will
not be communicated to parents, and which information disclosure requires the child’s consent.
Nomenclature for data/sample identifiability • Standardised sample identifiability terminology should be used: coded (including single-coded
and double-coded), anonymised, and anonymous.
• Biobanking or genetic research consent forms should declare that anonymised or coded data
and samples cannot absolutely guarantee privacy.
Retention of and access to data/samples
Retention period(s) of data/samples • Consent forms should clearly distinguish between what is a legally required data/sample
retention period and a retention period decided upon by the researcher.
Access to data/samples • The policies and procedures for access to data and/or samples should be disclosed.
• These policies and procedures should consider the privacy impact (both to the parents and
child) of access to coded or anonymised information, including: organisational safeguards,
technological measures, physical measures, and ethics oversight.
• If feasible, researchers should disclose a method for listing all approved projects that are
accessing the data and/or samples.
Dove et al. BMC Medical Ethics 2013, 14:5 Page 8 of 10
http://www.biomedcentral.com/1472-6939/14/5
practices for drafting consent forms that address the
emerging issues discussed in this article (Table 2).
Conclusions
This article assesses Canadian paediatric consent forms in
light of emerging ethical issues in paediatric consent prac-
tices and identifies many gaps and inconsistencies among
the forms. Attention to the best practices could make a big
difference. To this end, we acknowledge that informed
consent is infinitely more complex than ethics guidelines
or law imply. The more those in the research community
recognise that information disclosed to a participant de-
pends on context (e.g. study project, location, resources)
and must go beyond mere duties of disclosure to actually
achieve understanding [51], the further researchers and
REBs can move towards ensuring there is genuine research
participation, and indeed, engagement [52-54]. To help get
there, future research should couple a thematic analysis of
paediatric consent or assent forms with surveys of views
and experiences of parents and children so as to offer a
more holistic approach to evaluating the strengths and
weaknesses of these forms.
At the same time, consent forms cannot and should not
include all issues under the sun, lest information overload
ensue. More information is not always better information;
indeed, consent form length may not materially affect the
quality of informed consent or consent rate [55,56]. While
some may perceive these best practices as cumbersome
additions to already unwieldy consent forms, appreciation
for contextualisation and brevity must be distinguished
from inappropriate omissions or unreasonable and unpre-
dictable ethical standards. We hope that the best practices
listed in Table 2 will be a useful guide for both the drafters
of consent forms and for REBs.
Ultimately, organisations, funding agencies, as well as
researchers and REBs, must work together to develop a
well-forged, dynamic ethical and legal toolbox to ensure
that consent forms disclose a sufficiently uniform level of
understandable information, including potentially conten-
tious issues, so that parents and children (to the extent
they are capable) can make an informed decision together
[57]. Attention to best practices will improve research col-
laboration, provide workable tools for researchers and eth-
ics boards, and improve the ethical tensions that can
occur in the tri-partite relationship between the child, par-
ents, and researchers. This enables us to ensure that the
most important participants in this process – children –
are fully protected, respected and given the opportunity to
grow up in a healthier and safer world.
Endnotes
a For this article, we adopt the definition of ‘child’ in
Article 1 of the UN Convention on the Rights of the
Child (1989): ‘. . .a child means every human being below
the age of eighteen years unless under the law applicable
to the child, majority is attained earlier.’
b For this article, ‘parent(s)’ also includes legal repre-
sentative(s) and legal guardian(s).
c Paediatric researchers and their institutions who re-
ceive funds from the three major Canadian federal funding
agencies (Canadian Institutes of Health Research, Sciences
and Engineering Research Council, and Social Sciences
and Humanities Research Council) must ensure that their
consent forms conform to ethical standards established by
the TCPS. Certain health and social service institutions in
provinces also have policies endorsing the TCPS (e.g. the
Ministère de la Santé et des Services sociaux du Québec).
Additional file
Additional file 1: Table of results for consent forms in addressing
emerging issues.
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